Attack #10

PTO/SB/08 (2-92)

Sheet 1 of 1

Application Number 08/812,393

Form PTO-1499 **COSURE CITATION** INFORMATION DE IN AN APPLICATION

Applicant

Linda A. SHERMAN et al.

(Use several sheets if necessary)

Filing Date March 5, 1997

Docket Number 313332000100

Group Art Unit 1801

U.S. PA	TENT DOCUMENTS			
nant Na	Nama	Class	Subalaga	D:1:.

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.						

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Transla YES	ation NO
	2.							

OTHER DOCUMENTS

		OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.)
Examiner Initials	Ref. No.	Title
MW	3.	Greenberg, P.D. Adv Immunol (1991) 49:281-355
w	4.	Yanuck, M. et al. Cancer Res (1993) 53:3257-3261
w	5.	Houbiers, J.G.A. et al. Eur J Immunol (1993) 23:2072-2077
ww	6.	Peoples, G.E. et al. Proc Natl Acad Sci USA (1995) 92:432-436
w	7.	Skipper, J. et al. J Exp Med (1993) 177:1493-1498
Cul	8.	Schwartz, R.H. Cell (1989) 57:1073-1081
CUN	9.	Browning, M.J. et al. Curr Opin Immunol (1992) 4:613-618
Mun	10.	Mizoguchi, H. et al. Science (1992) 258:1795-1798
in	11.	Vitiello, A. et al. J Exp Med (1991) 173:1007-1015
hun	12.	Theobald, M. et al Proc Natl Acad Sci USA (1995) 92:11993-11997.
nu	13.	Wegener, A.M.K. et al. Cell (1992) 68:83
Cull	14.	Engel, I. et al. Science (1992) 256:1318
Nin	15.	Irving, B.A. et al. Cell (1991) 64:891
NW	16.	Chung, S. et al. Proc Natl Acad Sci USA (1994) 91:12654-12658

EXAMINER:	Mun

DATE CONSIDERED: 11. 299

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Sheet 1 of 2

veral sheets if necessary)

Docket Number 313332000100

Application Number 08/812,393

Applicant

Linda A SHERMAN

Filing Date March 05, 1997

Group Art Unit 1801

Paper	MRKOT	7	U.S. PA	TENT DOCUMENTS	S		
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

			FOREIGN	PATENT DOCUMI	ENTS						
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO				
			OTHE	R DOCUMENTS	(inclu	ding author, title, D	ate, Pertinent	Pages, Etc.			
Examiner Initials	Ref. No.	Title	Title								
CWN	3.		, et al., "Retrovirus-metic progenitor cells,"			rug resistance į	genes in h	uman			
Nu	4.		M., <i>et al.</i> , "Human CI 995) 182:1315-1325	O8 transgene regulatio	n of HLA reco	ognition by mu	rine T cell	s," <i>J</i>			
Cul	5.		Le, A.T., et al., "Cytotoxic T cell responses in HLA-A2.1 transgenic mice," J Immunol (1989) 142(4):1366-1371								
Chin	6.	Lustgarten, J., et al., "Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8," <i>Human Immunology</i> (1997) 52(2):109-118									
MIW	7.		Man, S., et al., "Diversity and dominance among TCR recognizing HLA-A2.1 ⁺ influenza matrix peptide in human MHC Class I transgenic mice," <i>J Immunol</i> (1994) 153:4458-4467								
and	8.		Moller, P., et al., "The role of surface HLA-A,B,C molecule in tumour immunity," Cancer Surveys (1992) 13:101-127								
Cun	9.	identified th	Ressing, M.E., et al., "Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A *0201-binding peptides," J Immunol (1995) 154:5934-5943								
and	10.		Theobald, M., et al., "Targeting p53 as a general tumor antigen," Proc Natl Acad Sci USA (1995) 92:11993-11997								
CWN	11.		Wentworth, P.A., et al., "Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice," Eur J Immunol (1996) 26:97-101								
MW	12.		et al., "Dichotomy be J Immunol (1994) 24		cell epitopes	of the synthetic	peptide (T,G)-			

EXAMINER:	Mich	DATE CONSIDERED:	11.2.99	,

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.